title: [Levofloxacin hepatotoxicity. Higher risk in diabetics?].
abstract: Levofloxacin, commonly used in medical practice, is prescribed to treat pneumonia in patients with comorbidities. Although generally well tolerated and safe, it has a well-known, but rarely reported, undercharacterized and ill-identified hepatotoxicity, with an unknown signature. With cases of fulminant hepatitis, cholestasis episodes reveal an apparently benign progression. Its capability of interference with the glucidic metabolism is also well-known, and the susceptibility factors to these events include age, presence of multiple pathologies and polymedication. The link between Diabetes Mellitus and hepatotoxicity has not yet been identified. Nonetheless, reports of several cases in literature along with the identification of two cases in insulin-treated diabetics, lead to believe that this is a higher-risk group.
authors.affiliation: Serviço de Medicina Interna, Hospitais da Universidade de Coimbra, Coimbra, Portugal.
authors.forename: Joana
authors.initials: J
authors.lastname: Coelho
authors.forename: Carla
authors.initials: C
authors.lastname: Gonçalves
authors.forename: Sara
authors.initials: S
authors.lastname: Leitão
authors.forename: R
authors.initials: R
authors.lastname: Marques Dos Santos
authors.forename: J
authors.initials: J
authors.lastname: Nascimento Costa
mesh_terms: D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology* / Q000473:pathology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D005260:Female; D006801:Humans; D064704:Levofloxacin; D008099:Liver / Q000473:pathology; D008297:Male; D015242:Ofloxacin / Q000009:adverse effects*
chemical_list: D000900:Anti-Bacterial Agents; D064704:Levofloxacin; D015242:Ofloxacin